Form 1-K Issuer Information | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-K | OMB APPROVAL |
| OMB Number: 3235-0720 Estimated average burden hours per response: 600.0 |
1-K: Filer Information
Issuer CIK | 0001700800 |
Issuer CCC | XXXXXXXX |
Is filer a shell company? | Yes No |
Is the electronic copy of an official filing submitted in paper format? | |
File Number | |
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? | Yes No |
Successor File Number |
Is this a LIVE or TEST Filing? | LIVE TEST |
Would you like a Return Copy? | |
Period | 12-31-2021 |
Name | |
Phone | |
E-Mail Address |
Notify via Filing Website only? |
1-K: Tab 1 Notification
This Form 1-K is to provide an | Annual Report Special Financial Report for the fiscal year |
Fiscal Year End | 12-31-2021 |
Exact name of issuer as specified in the issuer's charter | Emerald Health Pharmaceuticals Inc. |
CIK | 0001700800 |
Jurisdiction of Incorporation / Organization | DELAWARE |
I.R.S. Employer Identification Number | 82-0669961 |
Address 1 | 5910 Pacific Center Blvd |
Address 2 | Suite 320 |
City | San Diego |
State/Country | CALIFORNIA |
Mailing Zip/ Postal Code | 92121 |
Phone | 858-352-0622 |
Title of each class of securities issued pursuant to Regulation A | Common stock, par value $0.0001 |
1-K: Summary Information Regarding Prior Offering and Proceeds
Summary Information
The following information must be provided for any Regulation A offering that has terminated or completed prior to the filing of this Form 1-K, unless such information has been previously reported in a manner permissible under Rule 257. If such information has been previously reported, check this box and leave the rest of Part I blank.
Commission File Number of the offering statement | 024-10810 |
Date of qualification of the offering statement | 03-29-2018 |
Date of commencement of the offering | 03-03-2019 |
Amount of securities qualified to be sold in the offering | 12850000 |
Amount of securities sold in the offering | 10422776 |
Price per security | $ 6.0000 |
The portion of aggregate sales attributable to securities sold on behalf of the issuer | $ 59996820.00 |
The portion of the aggregate sales attributable to securities sold on behalf of selling securityholders | $ 0.00 |
Fees in connection with this offering and names of service providers.
Underwriters - Name of Service Provider | Underwriters - Fees | $ | |
Sales Commissions - Name of Service Provider | Dalmore Group, LLC | Sales Commissions - Fee | $ 459923.00 |
Finders' Fees - Name of Service Provider | Finders' Fees - Fees | $ | |
Accounting or Audit - Name of Service Provider | Deloitte & Touche LLP | Accounting or Audit - Fees | $ 168605.00 |
Legal - Name of Service Provider | Greenberg Traurig, P.A. | Legal - Fees | $ 386006.00 |
Promoters - Name of Service Provider | Promoters - Fees | $ | |
Blue Sky Compliance - Name of Service Provider | Various states | Blue Sky Compliance - Fees | $ 48470.00 |
CRD Number of any broker or dealer listed | 136352 |
Net proceeds to the issuer | $ 56177893.00 |
Clarification of responses (if necessary) | Initially offered 10,000,000 shares at $5 per share. Price increase in July 2019, $6 per share. Additional 2,850,000 shares qualified in 2020. Fees include approximately $1.9 million for consultants/temp employees and $0.9 million other selling expenses. |